DRUG
LY3305677
Administered SC
Status
Completed
Phase
Phase 1
Enrollment
66
Locations
1
Results
Not posted
Publications
0
Study summary
The purpose of this study is to evaluate the safety of LY3305677 and any side effects that might be associated with it. This study will also look at how much LY3305677 gets into the blood stream, how long it takes the body to remove it. This study involves a single dose of LY3305677 administered by subcutaneous injection (SC). Participation in this study is expected to last up to 16 weeks.
Interventions
DRUG
Administered SC
DRUG
Administered SC
Timeline
First posted
Nov 23, 2016
Study start
Dec 5, 2016
Primary completion
Jul 14, 2017
Study completion
Jul 14, 2017
Results posted
Not reported
Registry updated
Jul 24, 2017
Outcomes
Number of Participants with One or More Serious Adverse Event(s) (SAEs) considered by the Investigator to be Related to Study Drug Administration
Time frame · Baseline to Study Completion (approximately 16 weeks)
Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3305677
Time frame · Day 1 Pre-dose through Day 85
Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3305677
Time frame · Day 1 Pre-dose through Day 85
Eligibility
Inclusion Criteria: * Overtly healthy as determined by medical history and physical examination * Male participants: will agree to use a reliable method of birth control and will not donate sperm during the study and for at least 3 months following the last dose of the investigational product * Female participants: women not of child-bearing potential due to surgical sterilization confirmed by medical history or menopause * First generation Japanese participants or non-Japanese participants * Have a body weight of more than 50 kilograms (kg) Exclusion Criteria: * Have participated within the last 3 months in a clinical trial involving an investigational product * Have known allergies to glucagon-like peptide-1 (GLP-1) analogs, or any components of the formulation, or history of significant atopy * Have an abnormality in the 12-lead electrocardiogram (ECG) at screening and/or Day -1 * Have undergone any form of bariatric surgery * Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis * Have a history of acute or chronic pancreatitis or elevation in serum lipase and/or amylase * Show evidence of human immunodeficiency virus (HIV) or Hepatitis B or C * Have used or intend to use medications that promote weight loss * Have donated blood of more than 500 milliliter (mL) within the last month * Currently smoke more than 10 cigarettes per day
Study locations
United Kingdom. Showing up to 24 locations stored in the fast local snapshot.
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Leeds, United Kingdom
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
West China Hospital · Metabolic Dysfunction-Associated Steatohepatitis · Hepatic Steatosis
Phase 2 / Phase 3
Not yet recruiting
60
2026-07
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
Tianjin Medical University · Type 2 Diabetes Mellitus (T2DM) · Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
Not applicable
Not yet recruiting
72
2026-07
Eli Lilly · Alcohol Use Disorder
Phase 2
Completed
308
2026-07
China National Center for Cardiovascular Diseases · Obesity & Overweight · Coronary Heart Disease
Phase 4
Not yet recruiting
116
2026-06
Shandong Provincial Hospital · Prediabetes · Impaired Fasting Glucose
Phase 4
Not yet recruiting
150
2026-06
Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes · Obesity
Phase 3
Completed
349
2026-06
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
200
2026-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.